Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SigmE7 + MtHSP70 DNA vaccine
- Development stage
- Preclinical
- Lead developer
- Chinese Academy of Medical Sciences
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**SigmE7 + MtHSP70 DNA vaccine** is an experimental therapeutic DNA vaccine developed for the treatment of HPV-related cancers, particularly cervical cancer. The vaccine is constructed by fusing a signal peptide gene sequence from human CD33 (Sig) upstream to a chimeric gene containing a modified human papillomavirus type 16 E7 antigen (mE7) and the heat shock protein 70 gene from Mycobacterium tuberculosis (MtHSP70). The primary mechanism involves the induction of strong HPV16 E7-specific CD8+ T cell immune responses, with the fusion protein acting both as a tumor antigen (E7) and an immunostimulatory adjuvant (HSP70), thereby enhancing cytotoxic T lymphocyte activation and antitumor effects in preclinical mouse models[1][2][3]. The addition of the CD33 signal sequence aims to further direct the fusion protein for secretion and antigen presentation.
- Other names
- SigmE7/MtHSP70 DNA vaccine
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)HPV16 E7 TCR (HPV16 E7-specific T-cell receptor)
Beyond the preview
Go deeper on SigmE7 + MtHSP70 DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SigmE7 + MtHSP70 DNA vaccine.